Abbott sales reached $13.01 billion in the third quarter of 2026, rising 14.5% from a year earlier. Comparable sales increased 7.0%, while adjusted earnings per share rose to $1.42 from $1.30.

Diagnostics and devices lead Abbott sales growth

Diagnostics produced $3.31 billion of revenue, up 46.7% on a reported basis. The division grew 6.4% on a comparable basis, separating underlying demand from acquisition effects.

Medical Devices remained Abbott’s largest segment with $5.83 billion in sales. Reported revenue increased 6.9%, while comparable growth reached 7.8%.

Nutrition sales rose 5.1% to $2.26 billion. Established Pharmaceutical Products added 6.8% and generated $1.61 billion.

Abbott Q3 2026 segment sales (billions of dollars)

Medical Devices — $5.826B

Diagnostics — $3.305B

Nutrition — $2.262B

Established Pharma — $1.614B

Source: Abbott third-quarter 2026 results. Bars are scaled to the largest segment.

The mix shows why investors should separate reported growth from organic performance. Diagnostics benefited most from portfolio changes, while devices delivered the strongest comparable expansion among Abbott’s major businesses.

Other recent earnings reports also show how segment mix can shape headline growth. AT&T’s fiber additions, Dime Community Bancshares’ margin gains, and Vicor’s AI power demand provide useful comparisons.

Guidance points to steady year-end growth

Abbott maintained its full-year comparable sales growth forecast of about 6.0%. The company also narrowed adjusted diluted EPS guidance to $5.50-$5.55.

The updated range implies management expects demand to remain resilient through year-end. However, reported segment growth may continue to differ from comparable growth because of acquisitions and currency movements.

Abbott reported GAAP diluted EPS of $0.53 for the quarter. Investors comparing the figures should note that adjusted EPS excludes specified items identified by the company.

The figures and guidance come from Abbott’s October 21 earnings release. The release date and the quarter’s operating period are separate: the announcement was published after the quarter ended.

Elsy Kanana is a financial and cryptocurrency journalist at FusionMarketNews, covering digital assets, blockchain technology, financial markets, and emerging fintech trends. Her reporting focuses on market movements, regulatory developments, and on-chain analytics, delivering clear, data-driven insights to readers worldwide.